Unity Biotechnology (NASDAQ:UBX) received a $14.00 target price from analysts at Morgan Stanley in a research report issued on Monday, TipRanks reports. The brokerage presently has a “buy” rating on the stock. Morgan Stanley’s target price would suggest a potential upside of 80.65% from the company’s previous close.
Separately, Zacks Investment Research lowered Hess Midstream Partners from a “hold” rating to a “sell” rating in a report on Tuesday, May 14th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $19.50.
NASDAQ UBX traded down $0.32 on Monday, reaching $7.75. 205,469 shares of the stock traded hands, compared to its average volume of 215,326. The stock’s fifty day moving average price is $8.58. The company has a market capitalization of $356.13 million, a P/E ratio of -3.05 and a beta of -0.24. Unity Biotechnology has a 12 month low of $7.30 and a 12 month high of $24.56.
Large investors have recently modified their holdings of the company. BNP Paribas Arbitrage SA grew its position in shares of Unity Biotechnology by 5,850.0% in the first quarter. BNP Paribas Arbitrage SA now owns 5,355 shares of the company’s stock valued at $43,000 after purchasing an additional 5,265 shares during the last quarter. Legal & General Group Plc grew its position in shares of Unity Biotechnology by 416.4% in the fourth quarter. Legal & General Group Plc now owns 3,863 shares of the company’s stock valued at $63,000 after purchasing an additional 3,115 shares during the last quarter. SG Americas Securities LLC acquired a new stake in Unity Biotechnology during the first quarter worth about $105,000. Citigroup Inc. grew its position in Unity Biotechnology by 374.7% during the fourth quarter. Citigroup Inc. now owns 6,589 shares of the company’s stock worth $107,000 after buying an additional 5,201 shares in the last quarter. Finally, Metropolitan Life Insurance Co. NY acquired a new stake in Unity Biotechnology during the fourth quarter worth about $144,000. 38.21% of the stock is currently owned by institutional investors.
About Unity Biotechnology
Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to extend human health span. The company's lead drug candidates include UBX0101 that is in Phase 1 clinical study for musculoskeletal disease; and UBX1967 for ophthalmologic diseases. It is also developing programs in pulmonary disorders.
Recommended Story: Is it better to buy a fund with a higher or lower NAV?
Receive News & Ratings for Unity Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unity Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.